Assessment of Blood and Follicular Fluid Immune Cell Constitution in Patients Undergoing in Vitro Fertilization

NCT ID: NCT01083745

Last Updated: 2010-03-18

Basic Information

• Recruitment Status: UNKNOWN
• Study Classification: OBSERVATIONAL

Brief Summary

The etiology of infertility in the majority of patients with poor response to ovarian stimulation remains unknown. This study will investigate the role of immune cells (T cells, B cells, dendritic cells and NK cells), that constitute the immune system which normally fights infection and cancer. We, the investigators, have found that specialized NK cells that help with new blood vessel formation, are found in the fluid surrounding the egg during IVF, only in patients with good response to ovarian stimulation. We now wish to expand our studies and correlate our findings to ovarian blood flow , as measured by 3D ultrasound and to the presence of other cells in the immune system.

Conditions

Infertility, Female

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

IVF patients - 1

Poor responders

No interventions assigned to this group

IVF patients - 2

Good responders

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Age 27-43 years
• Diagnosis of infertility due to endometriosis, severe male factor, tubal occlusion.
• Patient undergoing IVF

Exclusion Criteria

• Body mass index (BMI) > 38 kg/m2
• Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography
• Any current use of systemic steroid medication or any infertility treatment within 3 months of study enrollment.
• Any contraindication to being pregnant and carrying a pregnancy to term.
• Any ovarian or abdominal abnormality that may interfere with adequate TVS evaluation.
• Absence of one or two ovaries
• Clinically relevant systemic disease (e.g., Insulin-dependent diabetes, adrenal dysfunction, organic intracranial lesion, polycystic ovarian syndrome, hyperprolactinemia, or hypothalamic tumor) or serious illness (Neoplasia).
• History (within past 12 months) or current abuse of alcohol or drugs.
• Administration of any investigational drugs within three months prior to study enrollment.
• Any medical condition that may interfere with the absorption, distribution, metabolism or excretion of the study drugs, gastrointestinal diseases, mal absorption syndromes and liver dysfunction
• Unexplained gynecological bleeding.
• Ejaculated sperm is not sufficient for ICSI
• Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.
• Abnormal COH screening blood done for both partners, including: prolactin, thyroid stimulating hormone, HIV serology, Hepatitis B and C serology, Rubella, group and screen and syphilis serology prior to participation in study.
• Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial.

• Minimum Eligible Age: 27 Years
• Maximum Eligible Age: 43 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Hillel Yaffe Medical Center

OTHER_GOV

Sponsor Role: lead

Responsible Party

Hillel Yaffe Medical Center, IVF Unit

Locations

Hillel Yaffe Medical Center

Hadera, , Israel

Countries

Israel

Facility Contacts

Ofer Fainaru, MD

Role: primary

ofer.fainaru@hy.health.gov.il

972-4-6304750

Other Identifiers

022-10

Identifier Type: -

Identifier Source: org_study_id